Effect of small intestine bacterial overgrowth syndrome on the course of bronchial asthma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. The work was carried out to study the role and features of small intestine bacterial overgrowth (SIBO) in the pathogenesis of bronchial asthma (BA). Material and methods. 80 BA patients were included in the study. SIBO was detected by the hydrogen breath test with lactulose. The patients were treated by conventional basic therapy with combined drugs (long-acting β2-adrenomimetics, and inhaled glucocorticoids). Rifaximinum or Rifaximinum followed by probiotic feeding was administered for the SIBO treatment. Results. 30 (67%) and 15 (43%) of the patients with the allergic form and non-allergic asthma form suffered from SIBO respectively, p=0,028. Patients with SIBO and allergic asthma had higher levels of IgE in blood, eosinophils in sputum, impaired of the respiratory function (p<0,01). Gut microbiota modification by Rifaximinum and or probiotic feeding resulted in a decreased immune response (IgE) and improved in the function of respiration (p<0,001) and reduced levels of patient hospitalization (р<0,05). At the non-atopic asthma phenotype case, the microbiota correction contributed to an increase in the disease remission also.

Full Text

Restricted Access

About the authors

O. Yu Zolnikova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

N. D Potskherashvili

I.M. Sechenov First Moscow State Medical University (Sechenov University)

N. I Kokina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

A. S Trukhmanov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

V. T Ivashkin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

References

  1. Huffnagle G. The Microbiota and Allergies/Asthma. PLoS Pathog. 2010; 6 (5): e1000549. https://doi.org/10.1371/journal. ppat.1000549
  2. Ivashkin V, Zolnikova O., Potskherashvili N. A correction of a gut microflora composition for the allergic bronchial asthma complex therapy. Italian J. of Medicine. 2018; 12: 260 4. https://doi.org/10.4081/itjm.2018.1040
  3. Ivashkin V., Zolnikova O., Potskherashvili N. A metabolic activity of the intestinal microflora in patients with bronchial asthma. Clinics and Practice. 2019; 9: 1126. https:// doi.org/10.4081/cp.2019.1126
  4. Drell T., Larionova A., Voor T. et al. Differences in Gut Microbiota Between Atopic and Healthy Children. Curr Microbiol. 2015; 71 (2): 177-83. https://doi.org/10.1007/ s00284-015-0815-9.
  5. Rutten N., Gorissen D., Eck A. et al. Long Term Development of Gut Microbiota Composition in Atopic Children: Impact of Probiotics. PLoS One. 2015; 17: 10 (9): 3-17 e0137681. https://doi.org/10.1371/journal. pone.0137681
  6. Kang Y, Cai Y, Zhang H. Gut microbiota and allergy/asthma: From pathogenesis to new therapeutic strategies. Allergol Immunopathol. 2017; 45 (3): 305-9. https:// doi.org/10.1016/j.aller.2016.08.004.
  7. Fujimura K., Lynch S. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015; 17 (5): 592-602. https://doi. org/10.1016/j.chom.2015.04.007
  8. Wang Q., Li F., Liang B. et al. A metagenome-wide association study of gut microbiota in asthma in UK adults. BMC Microbiol. 2018; 18 (1): 114. https://doi. org/10.1186/s12866-018-1257-x.
  9. Kim D., Zeng M., Nunez G. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. Exp. Mol. Med. 2017; 49 (5): e339. https:// doi.org/10.1038/emm.2017.24
  10. Lynch SV. Gut Microbiota and Allergic Disease. New Insights. Ann Am. Thorac Soc. 2016; 1: 51-4. https://doi.org/10.1513/ AnnalsATS.201507-451MG.
  11. Frati F., Salvatori C., Incorvaia C. et al. The Role of the Microbiome in Asthma: The Gut-Lung Axis. Int J. Mol. Sci. 2018; 20 (1). pii: E123. https://doi.org/10.3390/ ijms20010123
  12. Sun M., Wu W., Liu Z., Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J. Gastroenterol. 2017; 52 (1): 1-8. https://doi. org/10.1007/s00535-016-1242-9.
  13. Chung K.F. Potential Role of the Lung Micro-biome in Shaping Asthma Phenotypes. Ann Am. Thorac Soc. 2017; 14: 326-31. https:// doi.org/10.1513/AnnalsATS.201702-138AW
  14. Barko P., McMichael M., Swanson K., Williams D. The Gastrointestinal Microbiome: A Review. J. Vet Intern Med. 2018; 32 (1): 9-25. https://doi.org/10.1111/jvim.14875.
  15. Kang Y, Cai Y. Future prospect of faecal microbiota transplantation as a potential therapy in asthma. Allergol Immunopathol. 2018; 46 (3): 307-9. https://doi. org/10.1016/j.aller.2017.04.008
  16. Tojo R., Suarez A., Clemente M. et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014; 20 (41): 15163-76. https://doi.org/10.3748/wjg.v20.i41.15163
  17. Huang Y, Boushey H. The microbiome in asthma. J. Allergy Clin. Immunol. 2015; 135 (1): 25-30. https://doi.org/10.10Wj. jaci.2014.11.011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies